Assert-IQ vs EchoGo® Heart Failure
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Assert-IQ provides long-term, continuous cardiac monitoring for the detection of arrhythmias using an insertable device. Conversely, EchoGo® Heart Failure is an AI platform that analyzes routine echocardiograms to diagnose Heart Failure with preserved Ejection Fraction (HFpEF). While both are cardiology AI tools for clinical decision support, they address distinct cardiac conditions and utilize different data inputs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Assert-IQu2122 is an Insertable Cardiac Monitor (ICM) system designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. EchoGou00ae Heart Failure is an AI platform that analyzes routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF), providing insights to support clinical decisions within 20 minutes.
Assert-IQu2122 is an insertable cardiac monitor that continuously records heart rhythms for up to six years, transmitting data via Bluetoothu00ae Low Energy to a secure cloud-based platform. EchoGou00ae Heart Failure analyzes routine echocardiogram video clips, specifically a single apical 4-chamber view, using AI to detect HFpEF.
Assert-IQu2122 provides continuous monitoring with remote capabilities and proactive clinician alerts for detected arrhythmias. EchoGou00ae Heart Failure delivers AI-powered insights for HFpEF detection within 20 minutes of analyzing echocardiogram video clips.
Assert-IQu2122 uses an enterprise pricing model, requiring physicians to contact Abbott Medical for institutional pricing details. EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers.
Assert-IQu2122 is indicated for monitoring and diagnostic evaluation of patients with suspected heart rhythm disorders, including various cardiac arrhythmias like atrial fibrillation, bradycardia, tachycardia, and sinus pauses. EchoGou00ae Heart Failure is specifically designed to detect Heart Failure with preserved Ejection Fraction (HFpEF) from echocardiograms.
Assert-IQu2122 features advanced AI algorithms for arrhythmia detection, which reduce false positives while maintaining high sensitivity, with studies showing 99.4% episode-based sensitivity for AF and a 93.6% positive predictive value for AF episodes. EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF, and has been shown to reclassify over 73% of non-diagnostic results from current clinical algorithms.